Txa127
Txa127 is a protein pharmaceutical. It is currently being investigated in clinical studies. It is known to target type-2 angiotensin II receptor and proto-oncogene Mas.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
146 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 13 | 8 | 8 | 6 | 2 | 37 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 2 | 2 | 2 | 5 | — | 10 |
| Heart failure | D006333 | HP_0001635 | I50 | 1 | 3 | — | 5 | — | 8 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 5 | 2 | — | 1 | — | 8 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 2 | — | — | 4 | 1 | 7 |
| Neoplasms | D009369 | — | C80 | 3 | 2 | 1 | 1 | — | 7 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 2 | 2 | 2 | — | 6 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 1 | — | — | 3 | 1 | 5 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | 3 | 1 | 1 | — | 4 |
| Ischemic stroke | D000083242 | — | — | — | 2 | 1 | 1 | — | 4 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | — | 2 | 7 | 4 | — | 3 | 12 |
| Essential hypertension | D000075222 | — | I10 | 2 | 3 | 2 | — | 1 | 8 |
| Infections | D007239 | EFO_0000544 | — | 2 | 4 | 2 | — | — | 5 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 1 | 4 | 2 | — | — | 4 |
| Communicable diseases | D003141 | — | — | 1 | 3 | 2 | — | — | 4 |
| Hypertrophy | D006984 | EFO_0002460 | — | — | 2 | 1 | — | 1 | 3 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | 1 | 2 | 1 | — | — | 2 |
| Sars-cov-2 | D000086402 | — | — | — | 2 | 2 | — | — | 2 |
| Hypertrophic cardiomyopathy | D002312 | EFO_0000538 | I42.1 | — | 2 | 1 | — | — | 2 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 1 | 1 | — | — | 2 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 3 | 1 | — | — | 1 | 5 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 2 | — | — | 1 | 4 |
| Hematologic neoplasms | D019337 | — | — | 1 | 3 | — | — | — | 4 |
| Acute lung injury | D055371 | EFO_0004610 | — | — | 1 | — | — | 2 | 3 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | 1 | — | — | — | 3 |
| Lymphoma | D008223 | — | C85.9 | 2 | 1 | — | — | — | 3 |
| Hodgkin disease | D006689 | — | C81 | 2 | 1 | — | — | — | 3 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | 1 | 2 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | — | 1 | — | — | 1 | 2 |
| Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 2 |
Show 43 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 9 | — | — | — | — | 9 |
| Myelodysplastic syndromes | D009190 | — | D46 | 3 | — | — | — | — | 3 |
| Leukemia | D007938 | — | C95 | 2 | — | — | — | — | 2 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | — | — | — | — | 2 |
| Primary myelofibrosis | D055728 | — | D47.4 | 2 | — | — | — | — | 2 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 2 | — | — | — | — | 2 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | — | — | — | — | 2 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 2 | — | — | — | — | 2 |
| Myeloid leukemia | D007951 | — | C92 | 2 | — | — | — | — | 2 |
| Preleukemia | D011289 | — | — | 2 | — | — | — | — | 2 |
Show 44 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | — | — | — | 1 | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | — | 1 | 1 |
| Eclampsia | D004461 | HP_0100601 | O15 | — | — | — | — | 1 | 1 |
| Left ventricular hypertrophy | D017379 | EFO_0003896 | — | — | — | — | — | 1 | 1 |
| Hypophosphatemia | D017674 | HP_0002148 | — | — | — | — | — | 1 | 1 |
| Familial hypophosphatemic rickets | D053098 | — | — | — | — | — | — | 1 | 1 |
| Renin-angiotensin system | D012084 | — | — | — | — | — | — | 1 | 1 |
| Pediatric obesity | D063766 | — | — | — | — | — | — | 1 | 1 |
| Lung injury | D055370 | — | S27.30 | — | — | — | — | 1 | 1 |
| Adrenocortical adenoma | D018246 | — | — | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Txa127 |
| INN | — |
| Description | Ile(5)-angiotensin II (1-7) is an angiotensin compound consisting of the linear heptapeptide sequence L-Asp-L-Arg-L-Val-L-Tyr-L-Ile-L-His-L-Pro. It has a role as a vasodilator agent. It is a tautomer of an Ile(5)-angiotensin II (1-7) dizwitterion. |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 39386-80-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545347 |
| ChEBI ID | 55438 |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 46 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use